



Molecular Detection, Pathogenesis, Antimicrobial Resistance and Mechanisms of Mycoplasma Isolates

Guest Editor:

Dr. M. Jacques Nsuami

Department of Medicine, School
of Medicine, Louisiana State
University Health Sciences
Center, New Orleans, LA 70112,
USA

Deadline for manuscript
submissions:

closed (30 November 2024)

Message from the Guest Editor

Over 100 bacterial species have been included in the genus *Mycoplasma*, living in humans, animals, and plants. Various *Mycoplasma* species cause joint changes and respiratory tract alterations in animals. In humans, many cases of community-acquired pneumonia are due to *Mycoplasma pneumoniae*. *Mycoplasma genitalium* and *Chlamydia trachomatis* caused an increased risk of HIV acquisition. *Mycoplasma hominis* has been associated with bacterial vaginosis, endometritis, and pelvic inflammatory disease. DNA amplification techniques are improving detection and enabling the identification and differentiation of several *Mycoplasma* species of veterinary and human significance. Molecular interactions of *Mycoplasmas* with their host's immune system and molecular mechanisms of antibiotic resistance against *Mycoplasmas* can thus be better understood.

This Special Issue invites the submission of original research manuscripts on the molecular detection of *Mycoplasmas*, the mechanisms by which they cause disease in humans or animals, the molecular mechanisms by which they evade their host's immune system, and mutations that lead to the development of antimicrobial resistance.

Dr. M. Jacques Nsuami





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi